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Mass Spectrometry (MS) has been widely reported for measuring the conversion of substrates
to products for enzyme assays. These measurements are typically performed by time-
consuming LC-MS to eliminate buffer salts that interfere with electrospray ionization MS.
However, matrix-assisted laser desorption ionization, time-of-flight MS (MALDI-TOF MS)
offers a label-free and direct readout of substrate and product, a fast sampling rate, and is
tolerant of many buffer salts, reagents, and compounds that are typically found in enzyme
reaction mixtures. In this report, a demonstration of how MALDI-TOF MS can be used to
directly measure ratios of substrates and products to produce IC50 curves for rapid enzyme
assays and compound screening is provided. Typical reproducibility parameters were 7%
RSD—a value comparable to ESI MS quantitative assays and well within the acceptable limits
for screening assays. The speed of the MALDI readout is currently about 10 s per sample, thus
allowing for over 7500 samples/day. From a simplicity standpoint, the enzymatic reaction
mixtures are prepared by liquid handling robots, the reactions are stopped by addition of a 10
times volume of acidic matrix solution, and the samples are simultaneously transferred to
MALDI target plate for analysis. Importantly, the ratios of substrate to product are of sufficient
reproducibility to eliminate the need for internal standards and, thus, minimize the cost and
increasing the speed of assay development. (J Am Soc Mass Spectrom 2006, 17, 815–822) ©
2006 American Society for Mass SpectrometryMass spectrometry is the standard for trace-level quantitation of compounds in complexmixtures [1–3]. In the pharmaceutical indus-
try, this has led to the routine use of these techniques to
monitor pharmacokinetics and bioavailability of drug
compounds in biological matrices [1–3]. These measure-
ments are typically performed by LC/ESI-MS/MS on
triple quadrupole instruments to minimize the effects of
other contaminating material in the mixtures [1–3].
Mass spectrometry techniques have also been widely
reported for measuring the conversion of substrates to
products for enzyme assays [4]. However, for many
enzymes with peptide substrates, ESI-MS approaches
have the added complication of dividing the substrate
and product into multiple peaks due to charge-state
distribution and thus affecting sensitivity and data
extraction. Conversely, MALDI-TOF MS offers a fast
sampling rate, primarily singly-charged peptides to
simplify the data analysis, and a desorption method
that is tolerant to many of the components present in
enzyme reaction mixtures. This eliminates the need for
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doi:10.1016/j.jasms.2006.02.019time-consuming prefractionation (i.e., LC separation)
before analysis.
Early in the development of high end commercial
MALDI-TOF instruments, Hsieh et al. [5] reported the
use of a MALDI-TOF MS approach for automated,
multi-enzyme compound screening. This approach
took advantage of the speed and sensitivity of MALDI-
TOF MS to provide a qualitative view of enzyme
inhibition in the presence of multiple inhibitors. Fur-
thermore, this group reported the ability to measure
loss of activity (inhibition) for several enzymes simul-
taneously by monitoring for the appearance of three
different enzyme products in one sample mixture. Like
most multiplexing experiments, compound mixtures
that showed activity could then be evaluated as indi-
vidual components to determine which compound was
responsible for the inhibitory activity. While this report
demonstrated a qualitative measurement of enzyme
inhibition, quantitative measurements are necessary for
enzyme kinetics and the production of comparative IC50
values to rank inhibitor potency. Unfortunately, the
reproducibility and quantitative capabilities of MALDI
have always been questionable when compared to ESI
methods. However, a growing body of literature has
indicated that MALDI-TOF MS approaches can be
effectively used for quantitative measurements [6–10].
These reports include direct quantitation of both small
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relative quantitation of tagged peptides for proteomics
studies [10], and quantitative measurements of enzyme
reactions [11]. As is the case with ESI-MS/MS ap-
proaches, many of these methods rely on internal
standards for the quantitation. For screening assays, a
direct readout that requires no internal standard would
be preferred because it would save the time and cost of
synthesizing a suitable internal standard.
In this report, MALDI-TOF MS is evaluated as a tool
to directly measure ratios of substrates and products to
produce IC50 curves for rapid inhibitor compound
screening. The general applicability of this approach for
kinases (both ser/thr and tyr) and a series of related
hydroxylases is assessed, and various parameters such
as linearity and reproducibility are addressed. In addi-
tion, the application is extended to include both rank
order of inhibitory potency and selectivity measure-
ment for compounds against related enzymes. Further-
more, the advantages of this approach compared to
traditional screening and other mass spectrometry
methods is presented. Finally, the progress toward
automating the overall process using commercially
available products is discussed.
Experimental
Materials
-Cyano-4-hydroxycinnamic acid, -CHCA, (#C2020)
was from Sigma-Aldrich (St. Louis, MO). Ammonium
monobasic phosphate (#0776-01) was from J. T. Baker.
Kemptide (#22,593) and phosphorylated kemptide
(#60,528) were purchased from AnaSpec, Inc. (San Jose,
CA). Neurogranin, the PKC substrate peptide
(#V5611), was purchased from Promega (Madison, WI).
All other substrate peptides (including the phosphory-
lated form of neurogranin) were synthesized by an
in-house facility and purified to greater than 90% before
use in the assays. Staurosporine (#EI156-1000) was
purchased from Biomol (Plymouth Meeting, PA). Pro-
tein Kinase C- (PKC, #12,946) and cAMP-dependent
Protein Kinase, catalytic subunit (PKA, #V5161) were
purchased from Upstate Biotech (Charlottesville, VA)
and Promega, respectively. PKC activation buffer
(#V226A) were purchased from Promega and used
according to the supplier’s instructions.
Enzyme Assays and Sample Preparation
All assay reactions were prepared as 10  10 arrays in
the center section of a 384-well plate (Costar 3688,
Corning Corporation, Corning, NY) using a Beckman
Coulter Multimek (Fullerton, CA) equipped with 384-
well low volume transfer head. Compound dilutions
and the peptide substrate containing the necessary
cofactors (i.e., ATP, lipids, etc.) were prepared on sep-
arate plates using a Beckman Coulter Biomek 2000
workstation. The reactions were initiated, stopped, andtransferred to MALDI target plates in the following
order: (1) Five L was transferred from the compound
dilution plate to the assay plate containing 20 L
enzyme and the appropriate buffer; (2) 25 L of the
substrate peptide mixture (including cofactors) was
transferred to the assay plate to start the reaction; (3)
assay plates were incubated at RT for 30 to 60 min,
depending on the specific enzyme assay; (4) the reac-
tions were stopped by transferring 5 L of the reaction
mixture into 50 L of matrix solution (5 mg/mL of
-CHCA in 50% acetonitrile/H2O, 0.1% TFA, 5 mM
ammonium monobasic phosphate; (5) two L of the
stopped reaction mixture was transferred onto a
MALDI-TOF MS target plate, maintaining the original
10  10 array. The specific assay conditions for each
enzyme reaction were as follows: PKA—enzyme activ-
ity was measured using 2.7 units/well PKA in 40 mM
Tris:HCl, pH 7.5, containing 20 mM MgCl2, 0.1 mg/mL
BSA, 50 M ATP, and 50 M kemptide substrate.
Standard incubations for PKA were 30 min at RT.
PKC—Enzyme activity was measured using 6 ng/well
PKC in Promega activation buffer, plus 0.1 mg/mL
BSA, 50 M ATP, 200 M EDTA, 400 M CaCl2, and 25
M neurogranin substrate. Standard incubation condi-
tions for PKC were 30 min at RT.
MALDI-TOF MS
All spectra were collected on an Applied Biosystems
(Foster City, CA) 4700 Proteomics Analyzer MALDI-
TOF mass spectrometer equipped with a Nd:YAG laser
(355 nm, 3 ns pulse width, 200 Hz repetition rate) in
either positive or negative ion reflector mode as indi-
cated. The system was operated with the 4700 Explorer
software, version 2.0 or 3.0. Automated acquisition
parameters were adjusted to capture and average only
those individual spectra within defined success criteria.
Specifically, signal intensities for the substrate peptide
were set to a minimum threshold of 3000 counts and a
maximum intensity of 65,000 counts. This ensured that
neither null spectra nor saturated spectra were aver-
aged into the final readout. Depending on the substrate
peptide used, between 1000 and 2000 laser shots were
averaged from a minimum of 25 random positions from
each sample spot. Data were collected in triplicate from
three successive days (unless otherwise noted) to cap-
ture the maximum variability related to preparation of
the enzyme reactions, transfer of samples to MALDI
target plates, data collection, and data extraction.
Data Analysis
The isotope cluster areas for the peptide substrate and
product peaks were extracted into a Microsoft Excel
worksheet from the 10  10 array of spectral data
simultaneously using the automated analysis function
provided within the 4700 Explore software. An algo-
rithm within the 4700 Explorer analysis tools software
defined the isotope cluster area based on the molecular
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tides. For further details about the background subtrac-
tion, peak thresholds, and determining the baseline for
calculating the peak areas, contact Applied Biosystems,
(Framingham, MA). The percent conversion (% C) of
substrate to product was calculated as the cluster area
of the product (P) divide by the sum of the cluster areas
of the substrate (S) and product multiplied by 100 as
represented by eq 1:
%C [P ⁄ (P S)] 100 (1)
Eq 1 is a measure of the ratio of product to substrate
then solving for the % C. However, for concentration-
dependent inhibition studies, inhibition was plotted as
% maximal activity (% MA) for the following reason. To
measure inhibition of the enzyme activity, one must
measure the degree to which that activity (% C) was
curtailed. Thus the concentration-dependant inhibition
data were plotted as % MA where the maximal activity
is the % C measured in control reactions (with no
inhibitor) as represented in eq 2:
%MA (%C with inhibitor ⁄%C with
no inhibitor) 100 (2)
Thus, the % MA is the measurement of the degree of
inhibition.
Results and Discussion
Measuring Enzyme Activity by MALDI-TOF MS
Mass spectrometry is ideally suited for any enzyme
assay that results in a mass shift from substrate to
product. For enzymes with peptide substrates, MALDI-
TOF MS offers the advantage of speed, simplified
spectra, and minimal sample handling. As a demonstra-
tion of the data obtained using this approach, kemptide
substrate was incubated in the presence or absence of
PKA and spotted onto a MALDI target plate as de-
scribed in the Experimental section. The resulting mass
increase of 80 Da for the phosphorylation reaction
corresponding to the expected enzyme activity, was
readily detected (Figure 1). Similar results were ob-
tained for other kinases and when incubating a hydrox-
ylase enzyme with its peptide substrate to produce a
mass increase of 16 Da corresponding to the hydroxy-
lation reaction. While detection of the expected mass
shift are indicative of enzyme activity, the relative
quantitative relationship between the peak areas of the
substrate and product as measured by MALDI-TOF MS
remained to be determined.
For kinase reactions, one might expect dramatic
changes in the ionization and detection efficiencies due
to the increased acidity of the phosphorylated product
when compared to the substrate peptide. One way to
address this issue would be to use a deuterated internal
standard for the phosphorylated product thus minimiz-ing issues related to ionization efficiency differences.
This has been the method of choice for quantitative MS
for many years and has also recently been demon-
strated by MALDI-TOF MS for small molecules [6, 8]
and larger biomolecules [7]. However, to minimize the
cost and maximize the speed of such direct quantitative
experiments, we investigated whether simple ratios of
substrate to product maintained a linear relationship
that could then allow for accurate relative measure-
ments to be made without internal standards. To inves-
tigate the linearity of the MS response, 50 M total
peptide mixtures of kemptide and phosphorylated
kemptide were spotted at known molar ratios onto the
MALDI target plate. The ratios included 0, 2.5, 5, 10, 15,
20, 25, 30, 35, 40, 45, and 50% product. Replicate
samples of each ratio were prepared and analyzed on
six separate days. Spectra were collected in negative ion
reflector mode as described in the Experimental section.
The percent product measured by MALDI-TOF MS was
calculated as the isotope cluster area for the product
(phosphorylated kemptide) divided by the sum of the
cluster areas of the substrate (kemptide) plus the prod-
uct multiplied by 100. The average for the six replicates
was plotted against the known molar ratios to produce
the following best fit linear regression equation: y 
1.08x  3.6; r^2  0.998, with %RSD across all data
points 8.0%. The limit of detection was arbitrarily set
to 2.5% product since this was the lowest value that we
validated for relative quantitation using standard molar
mixtures of substrate and product. The precision of
Figure 1. MALDI-TOF MS profiles for the enzyme reaction for
PKA. Upper panel: Peptide substrate (kemptide) with buffers but
no enzyme. Lower panel: Peptide substrates incubated with
enzyme for 30 min resulting in the conversion of a portion of the
substrate to the expected phosphorylated product. The position of
the phosphorylation was confirmed by MS/MS fragmentation by
TOF/TOF analysis (data not shown).measurement at the 2.5% product level were also below
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estimate for the phosphorylated product compared to
the known molar ratios (slope  1.08). This was consis-
tent with expectations since these data were collected in
negative ion mode which would favor the ionization
and detection of the phosphorylated product. Con-
versely, data collection in the positive ion mode pro-
duced a slight underestimate for the phosphorylated
product (y  0.89x 1.01; r^2  0.992 with %RSD
across all data points 7.8%). Importantly however, in
either case, the ratio of substrate to product produced a
linear relationship, thus allowing for direct compari-
sons of relative enzyme activity for kinetics measure-
ments. The negative ion mode was chosen in most cases
as it minimized the level of Na, K, or NH4
 adducts
detected and, thus, simplified the data analysis.
Molar versus MS readout comparisons of substrate/
product combinations for additional enzymes (includ-
ing, other serine/theronine and tyrosine kinases, and a
hydroxylase enzyme) all yielded linear relationships
with correlation coefficient (r^2) values greater than
0.985 (data not shown), thus suggesting that this ap-
proach may be generally applicable to any enzyme
assay utilizing a peptide substrates that produces a
measurable mass shift. Furthermore, the effect of total
peptide concentration (from 5 to 500 M) was evaluated
to determine whether higher molar concentrations of
total peptide (substrate and product combine) would
result in some deleterious or selective ionization of the
substrates or products. Similar to the results presented
above, the linear relationship was maintained across the
peptide concentrations range with linear (r^2) values all
greater than 0.985 (data not shown). Taken together,
these results suggest that simple ratios of substrates and
products measured by MALDI-TOF MS are sufficient to
measure relative enzyme activity and thus be applicable
to screening the relative potencies of inhibitory com-
pounds.
Another consideration when using substrate/prod-
uct ratios to measure initial rate kinetics is that as the
substrate begins to be depleted, the rate of conversion to
product decreases rapidly. For ideal kinetic measure-
ments, excess substrate would be used with direct
quantitation of the product. However, by evaluating
enzyme reactions at early stages, the initial rates can be
maintained. Typically one targets the assay so that the
product never exceeds 10% of the substrate concentra-
tion; however, when evaluating substrate/product ra-
tios, the signal to noise begins to suffer at less than 20%
conversions. Therefore, to determine the conditions at
which the enzyme reaction maintained a close approx-
imation of initial rate with sufficient signal to get an
accurate readout, each enzyme reaction was evaluated
through a time-course and at various enzyme concen-
trations to determine the linear range of the assay. The
data from the time-course for PKA is shown in Figure 2.
For the various classes of enzymes measured to date,
the time and/or enzyme concentration could be ad-
justed to maintain a linear (initial) rate up to about 40%conversion of substrate to product. At higher percent-
ages of conversion, the velocity slowed down signifi-
cantly due to depletion of substrate. Thus by setting up
the control reactions to convert under 40% of substrate
to product, a reasonable approximation of initial veloc-
ity could be maintained without need for saturating
levels of substrate or isotopically-labeled internal stan-
dards.
Accuracy and Precision
For drug discovery and lead optimization, screening of
compounds for inhibitory potency is central to the
process. The process typically takes advantage of a
known inhibitor as an introductory benchmark com-
pound to develop and validate the assay and as an
entry point for comparing potencies against new com-
pounds. As a first step toward validating the utility of
MALDI-TOF MS as a readout for these inhibitor assays,
the reproducibility of the assay in a concentration-
dependent inhibitor study was evaluated over 21 days
(Figure 3). To capture the precision of these MS mea-
surements (including the variability of sample prepara-
tion and analysis), the relative response from the con-
trol reactions were monitored over this same 21 day
period. Experimentally, 10 control enzyme reactions
were included on each 10  10 array to establish the
baseline of control activity (maximal activity). These
values were averaged for each plate and used to calcu-
late the % maximal activity as described in eq 2 in the
Experimental section. Figure 3a shows the mean and
standard deviation for 10 sets of control reactions across
Figure 2. PKA enzyme titration and time-course at fixed sub-
strate and ATP. To select an enzyme concentration and standard
reaction time within an approximate linear range of the reaction
(initial rate), a time-course at various PKA concentrations was
evaluated. MALDI-TOF MS data were collected at the indicated
time points. The data points represent the average and standard
deviation of triplicate samples. The shaded area on the graph
represents the target range (20–40%) for measuring the % product
formed by MALDI-TOF MS. For this kinase, 2.7 units of enzyme
for 30 min was chosen as the standard reaction conditions for
further inhibitor screening.21 days. The overall mean from 10 replicates of the PKA
of 23
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36.0%  2.38. This converts to a relative standard
deviation of 7% which is comparable to those pro-
duced for ESI-based quantitative measurements [1].
Thus the MS readout is demonstrated to have excellent
precision even with all the variables associated with the
sample preparations, data collection and data analysis.
The ten IC50 inhibition curves for the benchmark com-
pound (staurosporine) were plotted in panel 3B. The
calculated IC50 values for PKA averaged about 29.6 nM
with a range from about 23 to 37 nM (plotted individ-
ually in Figure 3a). Thus the relative ratios of substrate
and product peaks are sufficient to generate the preci-
sion and accuracy needed for relative quantitation and
screening assays.
Rank Ordering of Inhibitor Potency
Once the reproducibility and precision parameters were
established, the ability to rapidly screen compounds to
rank order inhibitor potency was investigated. Four
different compound classes (staurosporine and three
novel structures) were evaluated as inhibitors of PKA
and plotted in Figure 4. The IC50 curves clearly demon-
strated the ability to rank order compounds based on
potency. In this case, staurosporine was the most potent
inhibitor (IC50  32 nM), while compound C was the
least potent (IC50100 M).
Selectivity Measurements
The potency of a compound against a selected target is
Figure 3. Stability of PKA inhibitory measurem
PKA inhibition curves with staurosporine, a b
period of 21 days. (a) Variability of the control r
the panel (left axis). For the days indicated, th
plotted as a mean and standard deviation of 10 r
overall mean and standard deviation of 36.0% 
under 7%. The calculated IC50 values for stauro
portion of the panel (right axis). The values were
a concentration-dependent inhibition of PKA wi
period to show the reproducibility of these mea
(a) with the shaded area showing an IC50 rangeonly the first step in the drug discovery pipeline. Giventhat many enzymes exist as members of enzyme fami-
lies with similar mechanism but often different func-
tions, a potent inhibitor may only be useful as a drug if
it can be demonstrated to be selective for the given
target without interfering with other related enzymes.
To that end, assays that allow for a comparison between
potency of the inhibitor for the target enzyme and
related enzymes are needed. To test this method for
selectivity measurement, the relative potency of stauro-
over three weeks. Variability measurements and
mark kinase inhibitor, were generated over a
on over 21 days is plotted in the upper portion
roduct from 10 replicate control samples was
ates on each day. Over the 21 days evaluated an
8 was determined resulting in a % RSD of just
ne were also plotted for each day in the lower
ed from the individual IC50 curves shown in (b),
urosporine measured on 10 days over a 21 day
ents. The individual IC50 values are plotted in
–37 nM across the time period.
Figure 4. Rank ordering of PKA inhibitor potency. Enzyme
assays were run with the indicated concentration of staurosporine
and three novel compounds as described in the Experimental
section. The percent maximal activity of substrate to product, as
measured by peak cluster areas using MALDI-TOF MS, was
plotted versus log compound concentration. The resulting com-










produce the rank order of compound potency as inhibitors.
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PKA and PKC. As plotted in Figure 5, staurosporine
was 10 times more potent as an inhibitor for PKC as
compared to PKA. This is in agreement with literature
reports on the relative inhibitory selectivity of stauro-
sporine for these related enzymes [12, 13].
Similar selectivity assays have been developed for a
series of Src family tyrosine kinases and a series of
related hydroxylase enzymes. Like the PKA and PKC
example shown here, the rank order and selectively of
inhibitor potency could be readily determined using
substrate/product ratios from the MALDI-TOF MS
readout without need for internal standard or molar
quantitation curves. Thus this approach has greatly
improved the speed and cut down on the cost of our
compound screening assays as compared to either tra-
ditional fluorescence or radiolabeled screening methods
or LC-MS/MS based quantitative readout methods.
Automation
The current method is dependent on our ability to get
the enzyme reaction mixtures onto the MALDI target
plate. Given that the AB 4700 Proteomics Analyzer has
a target plate with a 2  2 in. footprint, this was not
directly amenable to simultaneous transfer of samples
from a standard 96-well microtiter plate. Instead, to
advance the automation, a 10  10 array format was
developed in the center wells of 384-well plates, as this
produced a footprint of the desired dimensions for
direct sample transfer. Overall, the preparation of the
enzyme/inhibitor assays was done via robotic liquid
handling with the final quenching of the reaction by
dilution into the acidic MALDI matrix mixture (see
Experimental section for details). The automated spot-
Figure 5. Evaluating selectivity of staurosporine for PKC and
PKA. Substrate peptides for PKA and PKCwere incubated under
the established conditions for each enzyme to ensure linear
responses at initial rate conditions. 0.5 log dilutions of staurospor-
ine were evaluated in a concentration-dependent inhibition study.
The % MA was plotted versus staurosporine concentration to
produce the comparative IC50 curves.ting onto the target plate using the Multimek robotproduced a uniform 10 10 array, ideally suited for the
4700 system. The 10  10 array coupled with an
autoloader cassette on the source of the instrument
allowed for the loading of up to 24 plates (2400 samples)
for unattended data acquisition. Automated higher
density spotting onto 2  2 inch target plates has been
reported [5] and will be further investigated for this
application. Alternatively, commercial MALDI-TOF MS
instruments are available that accept microtiter plate-
sized sample targets. These have been shown to accom-
modate both 384- and 1536-well formats, thus dramat-
ically increasing the number of samples that could be
loaded for unattended data collection.
Why is an MS-Based Approach Desirable?
As described in the Introduction, mass spectrometry is
the industry standard for quantitative measurements
[1–3]. Given that the quantitation of a substrate and/or
product is the most direct measurement of an enzyme
activity, coupling mass spectrometry to screening as-
says would then provide the most direct means of
measuring inhibition of a given enzyme activity. Fur-
thermore, in a screening setting, the other critical fea-
tures of the assay readout are cost, speed, reproducibil-
ity, sensitivity, and automation. Issues related to false
positive or false negative readings are also important
considerations for a readout system. Importantly, the
direct MS readout measurement of substrates and prod-
ucts eliminates the issues related to the false positives or
negatives that can affect many of the traditional fluo-
rescence, chemiluminescence, or radiological assays.
Since these traditional assays often rely on a secondary
(or coupled) reaction for the readout, they also increase
the potential variability in the measurement. Further-
more, subsets of compounds from a screening library
are likely to have inherent fluorescence properties, or
may quench the fluorescence or chemiluminescence
readout causing several false positive or false negative
readouts from these assays. In addition, the use of
unlabeled peptide substrates eliminates the need for
costly fluorescent, chemiluminescent or radiolabeled
reagents. Thus, MS methods offer a direct measurement
of the substrate and product, avoid many of the false
positive/negative issues related to traditional screening
assays, and reduce the reagent costs.
MALDI-TOF MS approaches can offer significant
advantages over LC-MS approaches based on the min-
imal sample preparation needed and the speed of the
analysis. To date, nearly all the reports on the use of
MS-based assays for compound screening rely on
highly quantitative LC-MS approaches [14]. Some ex-
ceptions have included reports using porous silicon-
based surfaces (DIOS) [15, 16] and tailored target sur-
faces to enhance the interaction of ligands with target
proteins (SAMDI) [17]. In both of these approaches,
inhibition curves, relative quantitation measurements
and kinetic parameters were all demonstrated; how-
ever, these approaches require the preparation of spe-
821J Am Soc Mass Spectrom 2006, 17, 815–822 INHIBITOR SCREENING BY MALDI-TOF MScialized surfaces or reagents not widely available to the
research community. With the approach reported here,
the ability to use commercial instrumentation and sim-
ple peptide substrates coupled with standard enzyme
and inhibitor reactions for rapid compound screening is
demonstrated. The direct measurement of substrate and
product ratios provided the relative quantitation neces-
sary to both rank order compounds for potency and to
measure selectivity of compounds for related en-
zymes—all critical functions for screening assays.
Future Directions
This MALDI-TOF MS-based screening approach has
now been used to measure enzyme activity and inhibi-
tion for nine different enzymes with peptide substrates
ranging from 700 to 2800 Da. In all cases measured to
date, the substrate/product ratios produced the linear
relationships needed for relative quantitation. This sug-
gests that these methods are amenable to a wide range
of reactions with peptide substrates. Evaluation of a
wider range of substrates and enzyme classes is needed
to determine how broadly the approach can be used for
screening. Given that numerous reports have emerged
in the last few years demonstrating the quantitative
capabilities for MALDI MS for small (non-peptide)
molecules [6, 8, 9, 11], these results would imply that
the screening methods reported here could be extended
to enzymes with non-peptide substrates and products.
The ability to find a suitable matrix for specific substrate
product pairs and avoid interference from low molec-
ular weight matrix clusters would likely represent the
only challenge to making these approaches work. In
initial tests with some small molecule substrates, we
found that matrix interference could be minimized in
the mass range between 200 and 700 Da by adding
ammonium phosphate to the matrix [18] and by using a
sufficient quantity of substrate such that it was main-
tained above the matrix background (data not shown).
However, additional studies will be needed to deter-
mine the extent of such interference problems.
Even with the significant advantages that this ap-
proach offers, there are some limitations that are note-
worthy. One limitation of MALDI-TOF MS is the need
to have the analyte dry uniformly with the matrix
material to assure good laser desorption and detection
of the analytes. Thus, the ubiquitous use of DMSO for
storage and dilution of compound libraries poses some
challenges for cocrystallization with matrix. Similarly,
other buffer components (salts, detergents, etc) can
interfere with the formation of good matrix crystals.
Fortunately, the sensitivity of most MALDI-TOF MS
instruments (into the low femtomole range) is sufficient
to allow the reaction mixtures to be diluted into matrix
solution to minimize the effects of the buffer compo-
nents. As described in the Experimental section, by
using a 1:10 dilution of reaction mixtures into the matrix
solution, interference from reaction mixture compo-nents did not affect the MS readout in any of the nine
different screening assays we have evaluated to date.
Conclusions
We have demonstrated that MALDI-TOF MS offers a
valid readout for compound screening assays. The speed,
sensitivity, reduced cost, and reproducibility of this ap-
proach make it an ideal assay for dose-response curves for
comparative IC50 measurements. Additional advances in
laser pulse rates and sensitivity should improve the speed
to the point of rivaling true high-throughput screening.
Importantly, the direct nature of the MS measurement
ensures the minimization of the false positive and false
negative results that can plague other screening ap-
proaches. We have taken steps to validate the method and
show a variability of7% RSD. These data confirmed that
direct measurements of substrates and products ratios can
be used to produce IC50 curves for rapid enzyme assays
and compound screening without the need for labels or
additional internal standards.
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